The only Master’s specialisation in the Netherlands covering the function of our epigenome, a key factor in regulating gene expression and in a wide range of diseases.
Our skin cells, liver cells and blood cells all contain the same genetic information. Yet these are different types of cells, each performing their own specific tasks. How is this possible? The explanation lies in the epigenome: a heritable, cell-type specific set of chromosomal modifications, which regulates gene expression. Radboud University is specialised in studying the epigenome and is the only university in the Netherlands to offer a Master’s programme in this field of research.
The epigenome consists of small and reversible chemical modifications of the DNA or histone proteins, such as methylation, acetylation and phosphorylation. It changes the spatial structure of DNA, resulting in gene activation or repression. These processes are crucial for our health and also play a role in many diseases, like autoimmune diseases, cancer and neurological disorders. As opposed to modifications of the genome sequence itself, epigenetic modifications are reversible. You can therefore imagine the great potential of drugs that target epigenetic enzymes, so-called epi-drugs.
In this specialisation, you’ll look at a cell as one big and complex system. You’ll study epigenetic mechanisms during development and disease from different angles. This includes studying DNA and RNA by next-generation sequencing (epigenomics) and analysing proteins by mass spectrometry (proteomics). In addition, you‘ll be trained to design computational strategies that allow the integration of these multifaceted, high-throughput data sets into one system.
- Radboud University combines various state-of-the-art technologies – such as quantitative mass spectrometry and next-generation DNA sequencing – with downstream bioinformatics analyses in one department. This is unique in Europe.
- This programme allows you to work with researchers from the Radboud Institute for Molecular Life sciences (RIMLS), one of the leading multidisciplinary research institutes within this field of study worldwide.
- We have close contacts with high-profile medically oriented groups on the Radboud campus and with international institutes (EMBL, Max-Planck, Marie Curie, Cambridge, US-based labs, etc). As a Master’s student, you can choose to perform an internship in one of these related departments.
- Radboud University coordinates BLUEPRINT, a 30 million Euro European project focusing on the epigenomics of leukaemia. Master’s students have the opportunity to participate in this project.
As a Master’s student of Medical Epigenomics you’re trained in using state-of-the art technology in combination with biological software tools to study complete networks in cells in an unbiased manner. For example, you’ll know how to study the effects of drugs in the human body.
When you enter the job market, you’ll have:
- A thorough background of epigenetic mechanisms in health and disease, which is highly relevant in strongly rising field of epi-drug development
- Extensive and partly hands-on experience in state-of-the-art ‘omics’ technologies: next-generation sequencing, quantitative mass spectrometry and single cell technologies;
- Extensive expertise in designing, executing and interpreting scientific experiments in data-driven research;
- The computational skills needed to analyse large ‘omics’ datasets.
With this background, you can become a researcher at a:
- University or research institute;
- Pharmaceutical company, such as Synthon or Johnson & Johnson;
- Food company, like Danone or Unilever;
- Start-up company making use of -omics technology.
Apart from research into genomics and epigenomics, you could also work on topics such as miniaturising workflows, improving experimental devices, the interface between biology and informatics, medicine from a systems approach.
Or you can become a:
- Biological or medical consultant;
- Biology teacher;
- Policy coordinator, regarding genetic or medical issues;
- Patent attorney;
- Clinical research associate;
Each year, the Molecular Biology department (Prof. Henk Stunnenberg, Prof. Michiel Vermeulen) and the Molecular Developmental Biology department (Prof. Gert-Jan Veenstra) at the RIMLS offer between five and ten PhD positions. Of course, many graduates also apply for a PhD position at related departments in the Netherlands, or abroad.
- Systems biology
In the Medical Epigenomics specialisation you won’t zoom in on only one particular gene, protein or signalling pathway. Instead, you’ll regard the cell as one complete system. This comprehensive view allows you to, for example, model the impact of one particular epigenetic mutation on various parts and functions of the cell, or study the effects of a drug in an unbiased manner. One of the challenges of this systems biology approach is the processing and integration of large amounts of data. That’s why you’ll also be trained in computational biology. Once graduated, this will be a great advantage: you’ll be able to bridge the gap between biology, technology and informatics , and thus have a profile that is desperately needed in modern, data-driven biology.
- Multiple OMICS approaches
Studying cells in a systems biology approach means connecting processes at the level of the genome (genomics), epigenome (epigenomics), transcriptome (transcriptomics), proteome (proteomics), etc. In the Medical Epigenomics specialisation, you’ll get acquainted with all these different fields of study.
- Patient and animal samples
Numerous genetic diseases are not caused by genetic mutations, but by epigenetic mutations that influence the structure and function of chromatin. Think of:
- Autoimmune diseases, like rheumatoid arthritis and lupus
- Cancer, in the forms of leukaemia, colon cancer, prostate cancer and cervical cancer
- Neurological disorders, like Rett Syndrome, Alzheimer, Parkinson, Multiple Sclerosis, schizophrenia and autism
We investigate these diseases on a cellular level, focusing on the epigenetic mutations and the impact on various pathways in the cell. You’ll get the chance to participate in that research, and work with embryonic stem cell, patient, Xenopus or zebra fish samples.
See the website http://www.ru.nl/masters/medicalbiology/epigenomics
The Cancer MSc reflects the depth and breadth of research interests, from basic science to translational medicine, within the UCL Cancer Institute. The programme, taught by research scientists and academic clinicians, provides students with an in-depth look at the biology behind the disease processes which lead to cancer.
This programme offers a foundation in understanding cancer as a disease process and its associated therapies. Students learn about the approaches taken to predict, detect, monitor and treat cancer, alongside the cutting-edge research methods and techniques used to advance our understanding of this disease and design better treatment strategies.
Students undertake modules to the value of 180 credits.
The programme consists of two core modules (60 credits), four specialist modules (60 credits) and a research project (60 credits).
A Postgraduate Diploma (120 credits, full-time nine months) is offered.
A Postgraduate Certificate (60 credits, full-time 12 weeks) is offered.
All MSc students undertake a laboratory project, clinical trials project or systems biology/informatics project, which culminates in a 10,000–12,000 word dissertation and an oral research presentation.
Teaching and learning
Students develop their knowledge and understanding of cancer through lectures, self-study, database mining, wet-lab based practicals, clinical trial evaluations, laboratory training, assigned reading and self-learning. Each taught module is assessed by an unseen written examination and/or coursework. The research project is assessed by the dissertation (75%) and oral presentation (25%).
Further information on modules and degree structure is available on the department website: Cancer MSc
The knowledge and skills developed will be suitable for those in an industrial or healthcare setting, as well as those individuals contemplating a PhD or medical studies in cancer.
Skills include critical evaluation of scientific literature, experimental planning and design interpretation of data and results, presentation/public speaking skills, time management, working with a team, working independently and writing for various audiences.
UCL is one of Europe's largest and most productive centres of biomedical science, with an international reputation for leading basic, translational and clinical cancer research.
The UCL Cancer Institute brings together scientists from various disciplines to synergise multidisciplinary research into cancer, whose particular areas of expertise include: the biology of leukaemia, the infectious causes of cancer, the design of drugs that interact with DNA, antibody-directed therapies, the molecular pathology of cancer, signalling pathways in cancer, epigenetic changes in cancer, gene therapy, cancer stem cell biology, early phase clinical trials, and national and international clinical trials in solid tumours and blood cancers.
The Research Excellence Framework, or REF, is the system for assessing the quality of research in UK higher education institutions. The 2014 REF was carried out by the UK's higher education funding bodies, and the results used to allocate research funding from 2015/16.
The following REF score was awarded to the department: Cancer Institute
80% rated 4* (‘world-leading’) or 3* (‘internationally excellent’)
Learn more about the scope of UCL's research, and browse case studies, on our Research Impact website.
The University of Chester Haematology course is a taught postgraduate qualification lasting for one year full-time or two to four years part-time.
Students completing a range of modules followed by a research dissertation are awarded a full Master of Science degree. Students completing fewer modules, without a dissertation, may graduate instead with a Postgraduate Certificate or Postgraduate Diploma.
The MSc in Haematology is designed to enable you to develop an up-to-date, advanced understanding of the disorders of blood and blood-forming tissues. Utilising critical analytical skills, you will evaluate new developments in research into the blood sciences.
You will receive training in the skills required in the reading and interpretation of the literature and translating that into evidence-based practice. We aim to develop your research and writing skills so that you will be in a position to contribute to the scientific literature in an effective manner.
The course culminates in the Research Dissertation, which will be assessed through your production of two publishable scientific articles.
The content of the course is mapped to The Joint Royal Colleges of Physicians Training Board Speciality Training Curriculum for Haematology.
If biomedical or clinical research is your interest, successful completion of the MSc will allow you to directly register onto PhD study and join our team of researchers at the Institute of Medicine.
Our course investigates in detail mechanistic models of haematopoiesis and how knowledge of stem cell theory can inform the treatment of anaemia or leukaemia. Blood carries many hormones and cytokines; these can be used as biomarkers of disease, and we will examine the problems associated with some of these measurements. You will also review current guidelines and their evidence base in the therapeutic management of haematological problems, and explore potential new therapies.
Our course consists of taught modules and a Research Dissertation. We deliver taught modules as three-day intensive courses to facilitate attendance from students in employment. Weekly support sessions and journal club supplement learning – all held in our modern facilities in Bache Hall.
The modules given below are the latest example of the curriculum available on this degree programme. Please note that programme structures and individual modules are subject to change from time to time for reasons which include curriculum enhancement, staff changes, student numbers, improvements in technology, changes to placements or regulatory or external body requirements.
Evidence Based Medicine(Compulsory) (MD7001)
Analysis and Interpretation of Clinical Data(Optional) (MD7002)
Clinical Medicine(Compulsory) (MD7003)
Blood Sciences(Compulsory) (MD7005)
Therapeutic Advances in Treating Haematological Problems(Compulsory) (MD7022)
Case Investigations in Molecular Medicine(Compulsory) (MD7027)
Assessment and Consultation in Clinical Settings(Optional) (MD7069)
Research Dissertation(Compulsory) (MD7100)
You will be assessed via coursework assignments, which may focus on clinical reviews, laboratory reports, posters, oral presentations, or data manipulation exercises.
The following postgraduate funding may be available to study Haematology at the University of Chester.
Erasmus Masters Loans – Offering up to €18,000 for eligible students to study a Masters abroad.
FindAMasters Scholarships – Offering up to £5,000 to new UK, EU and international postgraduates.
Full Time (UK / EU): £6,390
Full Time (international): £11,850 (+£250 per academic year)
Part Time (UK / EU): £710 per 20 credits